Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nicotra

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
ESMO Gastrointestinal Oncology|February 6, 2026
Codon-specific <i>KRAS</i> mutations predict survival in advanced pancreatic cancerA Boilève, A Rousseau, M Hilmi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2022
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)A Bayle, F Peyraud, L Belcaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) studyA Bayle, L Belcaid, M Aldea, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
ESMO Gastrointestinal Oncology|February 6, 2026
Codon-specific <i>KRAS</i> mutations predict survival in advanced pancreatic cancerA Boilève, A Rousseau, M Hilmi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2022
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)A Bayle, F Peyraud, L Belcaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) studyA Bayle, L Belcaid, M Aldea, et al.
Pageof 3